/
IMCR
$30.42-$0.46 (-1.49%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.6B
51M shares
52-week range
$27.56 – $40.71
22% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
ADRC
Borrow rate
0.27%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-8.63
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.7M | $25.7M | $30.1M | $27.0M | $144.2M | $197.4M | $248.0M | $297.6M |
| Cost of revenue | $0 | $100.0M | $74.8M | $0 | $5.3M | $820.6K | $5.5M | $6.2M |
| Gross profit | $23.7M | −$74.3M | −$44.7M | $27.0M | $138.9M | $196.6M | $242.4M | $291.4M |
| Gross margin | 100.0% | -289.5% | -148.4% | 100.0% | 96.3% | 99.6% | 97.8% | 97.9% |
| R&D | $83.6M | $100.0M | $74.8M | $74.3M | $84.3M | $129.4M | $177.4M | $204.5M |
| Operating income | −$93.5M | −$118.3M | −$86.2M | −$129.4M | −$42.8M | −$47.2M | −$56.3M | −$33.7M |
| EBITDA | −$86.7M | −$111.6M | −$82.4M | −$123.6M | −$38.4M | −$40.9M | −$38.5M | $387.2K |
| Net income | −$71.6M | −$103.9M | −$74.1M | −$133.5M | −$43.5M | −$43.8M | −$40.8M | −$26.4M |
| Net margin | -302.8% | -404.9% | -246.0% | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% |
| EPS (diluted) | -2.62 | -3.81 | -2.33 | -3.00 | -0.95 | -0.89 | -1.02 | -0.53 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $447M | $0.12 | $-0.91–$1.51 | 10 |
| 2027 | $486M | $-0.45 | $-1.15–$0.23 | 9 |
| 2028 | $578M | $0.36 | $-1.08–$2.95 | 9 |
| 2029 | $812M | $3.28 | $2.79–$3.69 | 3 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Immunocore Holdings plc American Depositary Shares
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
www.immunocore.com- Employees
- 524
- IPO / List date
- Feb 5, 2021
- HQ
- OXFORDSHIRE, X0
Held by traders on TradeandTell
No one on the platform currently holds IMCR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 164,000 | $4.9M |
| Bridgewater Associatesas of 2026-03-31 | 18,930 | $570.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMCR yet.
